Most Read Articles
5 days ago
Higher circulating levels of docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA) appear to be protective against incident atherothrombotic and cardioembolic strokes, respectively, according to a recent study.
Roshini Claire Anthony, 11 Oct 2017

The prevalence of resistant hypertension may be lower than expected, particularly once pseudo-resistant hypertension due to treatment nonadherence is taken into account, according to a presentation at the recent APCH 2017.

Pank Jit Sin, 07 Jan 2015

Cardiovascular diseases (CVD) have been the main cause of death in the Malaysian population since 2007. This trend has continued, with the number of people dying from CVD-related causes increasing year on year. 

Tristan Manalac, 6 days ago
Administration of a long-acting medication at the time that is most suitable for maximum patient compliance is the best approach in controlling blood pressure, said Dr. Trefor Morgan at the recently concluded 13th Asian-Pacific Congress of Hypertension (APCH 2017), held at the Suntec Singapore Convention and Exhibition Centre.

Expanding indications of TAVR in patients with aortic stenosis

Pearl Toh
20 Jul 2017
Dr Paul Chiam

Transcatheter aortic valve replacement (TAVR) is the standard of care for high-risk patients with severe aortic stenosis (AS), and may be superior to open surgery in patients with lower risk as newer generation devices emerge, according to a presentation at the APSC Congress 2017 in Singapore.

With more data surfacing in time to come, TAVR will probably be shown to be superior to open surgery in intermediate-risk patients, according to Dr Paul Chiam, senior consultant cardiologist at The Heart & Vascular Centre, Mount Elizabeth Hospital, Singapore.

In the initial PARTNER trial, TAVR significantly reduced the rates of all-cause mortality compared with open surgery among high-risk patients with severe AS, and the survival benefit has been demonstrated up to at least 5 years. [N Engl J Med 2010;363:1597-1607]

Moving down the risk scale to patients with intermediate risk, TAVR was shown to be noninferior to surgical aortic valve replacement (SAVR) in terms of the composite endpoint of all-cause mortality or disabling stroke at 2 years in the PARTNER 2A trial using the SAPIEN XT valves and in the SURTAVI trial using a self-expanding CoreValve or Evolut R bioprosthesis. [N Engl J Med 2016;374:1609-1620; N Engl J Med 2017;376:1321-1331]

While TAVR was associated with significantly improved AV haemodynamics and lower rates of stroke at 30 days, atrial fibrillation, acute kidney injury, and transfusion needs, it was also associated with greater residual aortic regurgitation, major vascular complications, and pacemaker requirement in SURTAVI, Chiam pointed out.

Similarly, durable clinical and haemodynamic results have been observed in Asian patients, with the first Asian patient (77-year-old male) who underwent TAVR via the transfemoral route still surviving up to 8.5 years to date after the procedure, said Chiam. [Singapore Med J 2009; 50:534-537]

For AS patients with degenerated aortic surgical bioprostheses, TAVR is an attractive option to avoid the need for open surgery, according to Chiam. In a small case-series study involving Asians who underwent valve-in-valve TAVR, satisfactory haemodynamic results and clinical improvement were sustained at 1 year, with no stroke, major vascular complication, or death reported (except one noncardiac death) at 1 year after the procedure. [Singapore Med J 2016;57:401-405]

Off-label use of TAVR in bicuspid valves, noncalcific AS and selected pure severe aortic regurgitation (AR) is also feasible, said Chiam. Performing TAVR in patients with pure AR might entail a greater need for the use of two valves, while a major concern to bear in mind for both groups of patients (with pure AR or bicuspid aortic valve stenosis) is the higher risk of valve embolization, he cautioned.

“Newer and better devices [are likely to] improve the results of the procedure,” said Chiam, who is optimistic that indications for TAVR will continue to expand as newer and more improved devices become available.

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
5 days ago
Higher circulating levels of docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA) appear to be protective against incident atherothrombotic and cardioembolic strokes, respectively, according to a recent study.
Roshini Claire Anthony, 11 Oct 2017

The prevalence of resistant hypertension may be lower than expected, particularly once pseudo-resistant hypertension due to treatment nonadherence is taken into account, according to a presentation at the recent APCH 2017.

Pank Jit Sin, 07 Jan 2015

Cardiovascular diseases (CVD) have been the main cause of death in the Malaysian population since 2007. This trend has continued, with the number of people dying from CVD-related causes increasing year on year. 

Tristan Manalac, 6 days ago
Administration of a long-acting medication at the time that is most suitable for maximum patient compliance is the best approach in controlling blood pressure, said Dr. Trefor Morgan at the recently concluded 13th Asian-Pacific Congress of Hypertension (APCH 2017), held at the Suntec Singapore Convention and Exhibition Centre.